Paradoxical dominant negative activity of an immunodeficiency-associated activating PIK3R1 variant

Patsy R Tomlinson,Rachel Knox,Olga Perisic,Helen Su,Gemma V Brierley,Roge L Williams,Robert K Semple

DOI: https://doi.org/10.1101/2023.11.02.565250

2024-11-05

Abstract:PIK3R1 encodes three regulatory subunits of class IA phosphoinositide 3-kinase (PI3K), each associating with any of three catalytic subunits, namely p110alpha, p110beta or p110delta. Constitutional PIK3R1 mutations cause diseases with a genotype-phenotype relationship not yet fully explained: heterozygous loss-of-function mutations cause SHORT syndrome, featuring insulin resistance and short stature attributed to reduced p110alpha function, while heterozygous activating mutations cause immunodeficiency, attributed to p110delta activation and known as APDS2. Surprisingly, APDS2 patients do not show features of p110alpha hyperactivation, but do commonly have SHORT syndrome-like features, suggesting p110alpha hypofunction. We sought to investigate this. In dermal fibroblasts from an APDS2 patient, we found no increased PI3K signalling, with p110delta expression markedly reduced. In preadipocytes, the APDS2 variant was potently dominant negative, associating with Irs1 and Irs2 but failing to heterodimerise with p110alpha. This attenuation of p110alpha signalling by a p110delta-activating PIK3R1 variant potentially explains co-incidence of gain-of-function and loss-of-function PIK3R1 phenotypes.

Biochemistry